Intervention Group for Alzheimer Disease
Phase-Based Progress Estimates
Effectiveness
Safety
Alzheimer Disease
TACAD - BehavioralEligibility
18+
Female
What conditions do you have?
Select
Eligibility
18+
Female
What conditions do you have?
Select
Study Summary
The purpose of the proposed study is to preliminarily evaluate Technology-based information and coaching/support program that is tailored for Asian American midlife women who are family caregivers of patients living with Alzheimer's disease (TACAD) in improving health outcomes of Asian American midlife women who are family caregivers of persons living with Alzheimer's disease (AACA) and their care recipients.
Treatment Effectiveness
Effectiveness Progress
Other trials for Alzheimer Disease
Study Objectives
11 Primary · 4 Secondary · Reporting Duration: Baseline, 1 months post intervention, 3 months post intervention
Month 3
Change in Acculturation Stress Scale (ASS) score from baseline
Change in Caregiver Activity Survey score from baseline
Change in Caregiver Assessment of Behavioral Skill Scale score from baseline
Change in EQ-5D-5L scale score from baseline
Change in Informant Questionnaire on Cognitive Decline in the Elderly (IQCODE) score from baseline
Change in Lawton ADL/IADL Scale score from baseline
Change in Midlife Women's Symptom Index from baseline
Change in Multidimensional Caregiver Strain Index from baseline
Change in Neuropsychological Inventory Questionnaire score from baseline
Change in Pearlin Mastery, Loss, and Competence Scale score from baseline
Change in Perceived Stress Scale score from baseline
Change in Quality of Life Scale in Alzheimer's Disease score from baseline
Change in Revised Memory and Behavior Problem Checklist score from baseline
Change in Social Readjustment Rating Scale (SRRS) score from baseline
Change in Ways of Coping Scale score from baseline
Trial Safety
Safety Progress
Other trials for Alzheimer Disease
Trial Design
2 Treatment Groups
Active Control Group
1 of 2
Intervention Group
1 of 2
Active Control
Experimental Treatment
60 Total Participants · 2 Treatment Groups
Primary Treatment: Intervention Group · No Placebo Group · N/A
Intervention GroupExperimental Group · 2 Interventions: TACAD, Alzheimer's Association website · Intervention Types: Behavioral, Behavioral
Active Control Group
Behavioral
ActiveComparator Group · 1 Intervention: Alzheimer's Association website · Intervention Types: BehavioralTrial Logistics
Trial Timeline
Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: baseline, 1 months post intervention, 3 months post intervention
Who is running the clinical trial?
Emory UniversityLead Sponsor
1,501 Previous Clinical Trials
2,677,496 Total Patients Enrolled
21 Trials studying Alzheimer Disease
1,967 Patients Enrolled for Alzheimer Disease
Eun-Ok Im, PhD, MPHPrincipal InvestigatorEmory University
2 Previous Clinical Trials
499 Total Patients Enrolled
Eligibility Criteria
Age 18+ · Female Participants · 8 Total Inclusion Criteria
Mark “yes” if the following statements are true for you:You are a family member of a person with PLAD.
About The Reviewer
Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.
Popular Clinical Trials
Top Clinical Trials in Cities
Relevant Clinical Trials
Unbiased Results
We believe in providing patients with all the options.Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.Back to top
Conditions
Cancer Related
Treatments